Company Description
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally.
The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia.
Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea.
Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma.
The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016.
Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Oct 5, 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 127 |
| CEO | Pavel Raifeld |
Contact Details
Address: 1350 Old Bayshore Highway, Suite 400 Burlingame, California 94010 United States | |
| Phone | 650 238 9600 |
| Website | inva.com |
Stock Details
| Ticker Symbol | INVA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001080014 |
| CUSIP Number | 45781M101 |
| ISIN Number | US45781M1018 |
| Employer ID | 94-3265960 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Pavel Raifeld C.F.A. | Chief Executive Officer and Director |
| Stephen Basso M.B.A. | Chief Financial Officer |
| Marianne Zhen CPA | Chief Accounting Officer and Secretary |
| Marcie Cain | Chief People Officer |
| Patricia M. Drake | Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc. |
| Dr. David Altarac M.D., MPA | Chief Medical Officer of IST |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 21, 2025 | 8-K | Current Report |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 28, 2025 | SCHEDULE 13G/A | Filing |
| Apr 8, 2025 | ARS | Filing |
| Apr 8, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 24, 2025 | 10-K/A | [Amend] Annual report |
| Mar 17, 2025 | SCHEDULE 13D/A | Filing |
| Mar 7, 2025 | SCHEDULE 13D/A | Filing |